140 related articles for article (PubMed ID: 31039766)
21. Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
Tamiya A; Isa SI; Taniguchi Y; Nakagawa H; Atagi S; Ando M; Koh Y
Clin Lung Cancer; 2021 May; 22(3):e336-e341. PubMed ID: 32641247
[TBL] [Abstract][Full Text] [Related]
22. The amount of activating EGFR mutations in circulating cell-free DNA is a marker to monitor osimertinib response.
Del Re M; Bordi P; Rofi E; Restante G; Valleggi S; Minari R; Crucitta S; Arrigoni E; Chella A; Morganti R; Tiseo M; Petrini I; Danesi R
Br J Cancer; 2018 Nov; 119(10):1252-1258. PubMed ID: 30397287
[TBL] [Abstract][Full Text] [Related]
23. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
[TBL] [Abstract][Full Text] [Related]
24. Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.
Lee K; Kim D; Yoon S; Lee DH; Kim SW
Eur J Cancer; 2021 May; 148():202-210. PubMed ID: 33744716
[TBL] [Abstract][Full Text] [Related]
25. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2.
Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC
Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719
[TBL] [Abstract][Full Text] [Related]
26. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in
Le X; Puri S; Negrao MV; Nilsson MB; Robichaux J; Boyle T; Hicks JK; Lovinger KL; Roarty E; Rinsurongkawong W; Tang M; Sun H; Elamin Y; Lacerda LC; Lewis J; Roth JA; Swisher SG; Lee JJ; William WN; Glisson BS; Zhang J; Papadimitrakopoulou VA; Gray JE; Heymach JV
Clin Cancer Res; 2018 Dec; 24(24):6195-6203. PubMed ID: 30228210
[TBL] [Abstract][Full Text] [Related]
27. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M.
Zhao S; Li X; Zhao C; Jiang T; Jia Y; Shi J; He Y; Li J; Zhou F; Gao G; Li W; Chen X; Su C; Ren S; Zhou C
Lung Cancer; 2019 Feb; 128():33-39. PubMed ID: 30642450
[TBL] [Abstract][Full Text] [Related]
28. Clinical implementation of plasma EGFR T790M testing using droplet digital PCR in TKI-resistant NSCLC patients.
Chan DLH; Toh GLX; Goh LL
Exp Mol Pathol; 2020 Oct; 116():104515. PubMed ID: 32738312
[TBL] [Abstract][Full Text] [Related]
29. MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
Nishiyama A; Takeuchi S; Adachi Y; Otani S; Tanimoto A; Sasaki M; Matsumoto S; Goto K; Yano S
Cancer Sci; 2020 Oct; 111(10):3813-3823. PubMed ID: 32735723
[TBL] [Abstract][Full Text] [Related]
30. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
[TBL] [Abstract][Full Text] [Related]
31. Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.
La Monica S; Minari R; Cretella D; Flammini L; Fumarola C; Bonelli M; Cavazzoni A; Digiacomo G; Galetti M; Madeddu D; Falco A; Lagrasta CA; Squadrilli A; Barocelli E; Romanel A; Quaini F; Petronini PG; Tiseo M; Alfieri R
J Exp Clin Cancer Res; 2019 May; 38(1):222. PubMed ID: 31138260
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
[TBL] [Abstract][Full Text] [Related]
33. Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.
Solassol J; Vendrell JA; Senal R; Audran P; Leenhardt F; Quantin X
Lung Cancer; 2019 Jul; 133():45-47. PubMed ID: 31200827
[TBL] [Abstract][Full Text] [Related]
34. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
35. Clinical implementation of circulating tumour DNA testing for
Spence T; Perera S; Weiss J; Grenier S; Ranich L; Shepherd F; Stockley TL
J Clin Pathol; 2021 Feb; 74(2):91-97. PubMed ID: 32471890
[TBL] [Abstract][Full Text] [Related]
36. Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib.
Ding PN; Becker T; Bray V; Chua W; Ma Y; Xu B; Lynch D; de Souza P; Roberts T
Thorac Cancer; 2019 Oct; 10(10):1879-1884. PubMed ID: 31414729
[TBL] [Abstract][Full Text] [Related]
37. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.
Mehlman C; Cadranel J; Rousseau-Bussac G; Lacave R; Pujals A; Girard N; Callens C; Gounant V; Théou-Anton N; Friard S; Trédaniel J; Blons H; Dujon C; Duchemann B; Schischmanoff PO; Chinet T; Giroux Leprieur E
Lung Cancer; 2019 Nov; 137():149-156. PubMed ID: 31600593
[TBL] [Abstract][Full Text] [Related]
38. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: A prospective observational study.
Ono T; Igawa S; Ozawa T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Katagiri M; Naoki K
Thorac Cancer; 2019 Apr; 10(4):880-889. PubMed ID: 30821083
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of epidermal growth factor receptor (EGFR) gene T790M mutation by droplet digital PCR and Super-ARMS PCR in plasma ctDNA samples of non-small cell lung cancer patients with the resistance to EGFR-tyrosine kinase inhibitor].
Cao ZY; Wu W; Hou LK; Zhang W; Gao CX; Wu CY; Zhang LP
Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):910-914. PubMed ID: 30522170
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
